Charles River Laboratories International, Inc. (CRL)
Automate Your Wheel Strategy on CRL
With Tiblio's Option Bot, you can configure your own wheel strategy including CRL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRL
- Rev/Share 79.3772
- Book/Share 63.9695
- PB 2.1996
- Debt/Equity 0.9347
- CurrentRatio 1.4332
- ROIC -0.023
- MktCap 6809891805.0
- FreeCF/Share 11.1143
- PFCF 12.0906
- PE -222.614
- Debt/Assets 0.3938
- DivYield 0
- ROE -0.0089
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CRL | Redburn Atlantic | Neutral | Buy | -- | $182 | May 23, 2025 |
| Upgrade | CRL | TD Cowen | Hold | Buy | -- | $179 | May 14, 2025 |
| Upgrade | CRL | Evercore ISI | In-line | Outperform | -- | $170 | May 8, 2025 |
| Downgrade | CRL | Goldman | Buy | Neutral | $190 | $170 | March 21, 2025 |
| Upgrade | CRL | Citigroup | Sell | Neutral | $155 | $175 | March 4, 2025 |
| Upgrade | CRL | Redburn Atlantic | Sell | Neutral | -- | $188 | March 3, 2025 |
| Downgrade | CRL | William Blair | Outperform | Market Perform | -- | -- | Jan. 22, 2025 |
| Downgrade | CRL | UBS | Buy | Neutral | $250 | $185 | Jan. 17, 2025 |
| Initiation | CRL | CLSA | -- | Underperform | -- | $167 | Oct. 23, 2024 |
| Initiation | CRL | Redburn Atlantic | -- | Sell | -- | -- | Oct. 14, 2024 |
News
Should You Continue to Hold Charles River Stock in Your Portfolio?
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Read More
S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments
Published: May 07, 2025 by: Investopedia
Sentiment: Neutral
The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.
Read More
Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. (NYSE:CRL ) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Max Smock - William Blair Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Ann Hynes - Mizuho Securities Dave Windley - Jefferies Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Kyle Crews - UBS Patrick Donnelly - Citi Casey Woodring - JPMorgan Charles Rhyee - TD Cowen …
Read More
Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization
Published: May 07, 2025 by: Benzinga
Sentiment: Positive
Charles River Laboratories International Inc CRL stock is trading higher on Wednesday after the company released better than expected first-quarter 2025 earnings.
Read More
Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More
Published: May 07, 2025 by: Investopedia
Sentiment: Positive
U.S. equities were little changed at midday as the market awaited the Federal Reserve's interest-rate decision coming this afternoon. The Dow Jones Industrial Average was higher, the Nasdaq was lower, and the S&P 500 was basically flat.
Read More
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.
Read More
Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago.
Read More
Charles River Laboratories Announces First-Quarter 2025 Results
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2025 Financial Results.
Read More
Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value.
Read More
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
Published: April 22, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology drugs.
Read More
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
Published: April 11, 2025 by: Benzinga
Sentiment: Neutral
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Read More
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Read More
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dave Windley - Jefferies Ann Hynes - Mizuho Justin Bowers - Deutsche Bank Lucas Romanski - TD Cowen Michael Ryskin - Bank of America Max Smock - William Blair Jacob Johnson - Stephens Patrick Donnelly - Citi Casey …
Read More
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Read More
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Is Now the Right Time to Hold on to Charles River Stock?
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
Read More
About Charles River Laboratories International, Inc. (CRL)
- IPO Date 2000-06-23
- Website https://www.criver.com
- Industry Medical - Diagnostics & Research
- CEO Mr. James C. Foster J.D.
- Employees 18700